{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Aldosterone",
        "LIAISON\u00ae Aldosterone Control Set",
        "LIAISON\u00ae Aldosterone Calibration Verifiers"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K130321",
    "Predicate Device Reference 510(k) Number(s)": [
        "K831178",
        "K071480",
        "K090104"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CJM",
        "JJX"
    ],
    "Summary Letter Date": "April 9, 2013",
    "Summary Letter Received Date": "February 27, 2013",
    "Submission Date": "February 7, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.1045",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Aldosterone test system",
        "Quality Control Material"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Aldosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "EDTA Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Competitive 2-step chemiluminescent assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "Calibration Verifier",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for LIAISON\u00ae Aldosterone assay, control set, and calibration verifiers using CLIA technology on the LIAISON\u00ae Analyzer for quantitative determination of aldosterone.",
    "Indications for Use Summary": "Intended for the quantitative determination of aldosterone in human serum, EDTA plasma, and urine to aid in diagnosis and treatment of primary aldosteronism, hypertension, selective hypoaldosteronism, edematous states, and other electrolyte imbalance conditions, performed on the LIAISON\u00ae Analyzer.",
    "fda_folder": "Clinical Chemistry"
}